The year 2015 marks the 30th anniversary of the
|
|
- Brook Bernadette Cox
- 5 years ago
- Views:
Transcription
1 Transfusion-related acute lung injury: three decades of progress but miles to go before we sleep The year 2015 marks the 30th anniversary of the original characterization of transfusion-related acute lung injury (TRALI). 1 The investigators at the Mayo Clinic gave form and substance to what physicians had previously observed that transfusion can act as the trigger for life-threatening acute respiratory distress. In the 1950s and 1960s others had used such descriptors as allergic pulmonary edema, pulmonary hypersensitivity, leukoagglutinin transfusion reaction, and noncardiogenic pulmonary edema, reflecting a poorly understood picture of what was believed to be a rare phenomenon. By identifying TRALI as a syndrome and establishing the importance of passive transfusion of HLA and HNA antibodies, the early work of Popovsky and colleagues 2 became the basis of subsequent research and efforts for mitigation and prevention. Now, three decades later, much satisfaction can be gleaned from what has been accomplished. However, key questions remain: 1. Do we have a complete understanding of the clinical manifestations of TRALI? 2. What is its frequency? 3. Who is at risk? 4. Are the prevention strategies effective? 5. What is the mechanism(s)? 6. What does the future hold? THE FIRST ERA: UNDERSTANDING THE PROBLEM In the first decade, approximately 1985 to 1995, we learned that the classic presentation of TRALI is lifethreatening and indistinguishable from adult respiratory distress syndrome (ARDS) and that because of severe, diffuse permeability pulmonary edema, hypoxemia, and hypotension, these patients require immediate mechanical ventilation as well as blood pressure support. Unlike those with ARDS, fully 80% recover within 96 hours. Any type of plasma-containing product, irrespective of volume, can cause TRALI. While there is consensus that the vast majority of classic TRALI occurs within 1 to 2 hours and the remainder within 6 hours, some doi: /trf VC 2015 AABB TRANSFUSION 2015;55; investigators believe that there are cases that present up to 24 hours from initiation of transfusion. 3 Although it is the severe cases which require resources and clinical skill to manage, the most frequent presentation may be relatively benign, limited to mild hypoxemia in the presence of white blood cell antibodies. 4 After the Popovsky and Moore publication in 1985, a plethora of articles from around the globe, representing hundreds of cases, appeared over the next 10 years. Investigators confirmed the Mayo findings of a prominent role for passively acquired antibody-laden plasma. In the majority of cases, antibody corresponded to recipient HLA or HNA epitopes. 5 Donors implicated in the HLA-positive cases were typically multiparous females. The reason that this complication of hemotherapy moved to center stage in the transfusion medicine world was its significant morbidity and mortality. The fatality rate of 5% to 20% exceeds that of any transfusion reaction. 6 In the setting of the intensive care unit, the death rate may be as high as 47%. 7 Once the Food and Drug Administration (FDA) initiated the collection of data for TRALI, it was clear that this syndrome is the leading cause of transfusion-associated death. In 2012 TRALI accounted for 43% of transfusionrelated deaths in the United States, and in the preceding decade, it had accounted for up to 65%. 8 The European experience is similar, where TRALI is the first or second most frequently reported transfusion-associated fatality. The significant resources expended to deal with its morbidity increase its importance, particularly in an era of health care cost constraint. HOW FREQUENTLY DOES TRALI OCCUR? Because of the prevention strategies now in place, the answer is much different today than it was in the 1980s. At the Mayo Clinic, where bedside transfusions are under the control of highly experienced transfusion medicine nurses, an incidence of 1 in 5000 plasmacontaining transfusions was established as the early benchmark. 1 Subsequent hospital-based, albeit retrospective, studies reported similar frequencies although the published rates of TRALI from European hemovigilance systems were lower by orders of magnitude. There were many reasons for the disparity, including the lack of common diagnostic criteria, differences in type of blood product involved reported, and passive versus active collection of data. The publication of case 930 TRANSFUSION Volume 55, May 2015
2 definitions from the 2004 Canadian consensus conference and National Heart, Lung, and Blood Institute Working Group were milestone events, 9,10 as they provided a common framework to diagnose the syndrome. The case definitions were based on clinical and radiologic parameters. Yet, some countries use an alternative approach in which imputability is scored. 11 Complicating matters further is how some transfusion services and donor centers distinguish and report TRALI, possible TRALI, and delayed TRALI (presentation beyond 24 hr). 12 These differences result in different thresholds for which a definitive diagnosis is made. In summary, we have a Tower of Babel in establishing a common assessment of the frequency. Before the implementation of risk reduction measures, evidence existed that TRALI is more frequent than the 1 in 5000 Mayo benchmark. In a prospective study in patients undergoing cardiopulmonary bypass, TRALI developed in 2.4% within 30 hours postsurgery. 13 In the medical intensive care unit, 8% of transfused patients followed prospectively developed acute lung injury. 14 In an active surveillance study of two tertiary care centers, the TRALI incidence in 2006, just before implementation of plasma risk reduction measures, was 2.57 per 10,000 units transfused (1:4000 units), dramatically higher than what was reported from passive hemovigilance systems, 15 but comparable to the earliest observations. Because the diagnosis of TRALI involves consideration of other confounders, most frequently hydrostatic pulmonary edema (transfusion-associated circulatory overload [TACO]), many cases of TRALI are most certainly overlooked or misdiagnosed. Supporting this view is the widely known case study of Kopko and coworkers 6 in which of 36 evaluable patients transfused from an index donor, only seven of 15 TRALI reactions were reported to the transfusion service, and of these, only two were reported to the regional blood center that collected the implicated plasma products. As TRALI and TACO can occur concurrently and because these pulmonary complications are frequently confused, the belief that many cases are undetected now receives additional credence WHO IS AT RISK? Both retrospective and prospective studies have identified common patient risk factors for TRALI. Most striking is mechanical ventilation, in which up to 33% of transfused patients develop acute lung injury. 7 A working assumption is that positive pressure ventilation causes neutrophil priming, which leads to pulmonary microvascular endothelial injury. This theory may explain why so many critical care patients develop TRALI. 16 Prospectively collected data indicate that massive transfusion, shock, positive fluid balance, chronic alcohol abuse, severe liver disease, and elevated pretransfusion levels of interleukin-8 are risk factors for the syndrome. Additionally, sepsis, hematologic malignancy, and emergency cardiac surgery have been implicated in retrospective studies. 13,16 In cardiac surgery extracorporeal circuits may serve to activate neutrophils. On the other hand, the cases at high risk for TRALI are also among the sickest patients who are commonly transfused, making proof of causality difficult. Transfusion risk factors have been found to play a role as well. These include plasma, whole blood, volume of HLA Class II antibody, and volume of anti-human neutrophil antigen. 15 The antibody predictors apply to all blood components, but it appears that larger plasma volume confers higher risk. From the study of Toy and colleagues, 16 no risk or little risk was associated with older red blood cell (RBC) units, noncognate or weak cognate Class II antibody, or Class I antibody. These data must be interpreted with caution as the number of studies that have investigated these issues are few and the level of evidence mixed. Caution should be applied to the relationship of RBC storage age, platelet (PLT) age, and the presence of bioactive lipids to TRALI, inasmuch as these factors have either been implicated or dismissed. Recent studies shed light on two demographic groups the elderly and children neither previously thought to have a prominent place in TRALI. A multivariate analysis of inpatient Medicare beneficiaries during 2007 through 2011 found that there was increased TRALI risk with plasma or PLT transfusions, in females and the young elderly (65-79 years). The inpatient mortality of 21% is at the upper end of what is reported in the literature. 17 The authors hypothesize that the decreased TRALI rate among the older elderly (>79 years) may reflect the age-related decline in innate immunity and, with it, impairment of neutrophil function. TRALI cases in children were thought to be rare. However, Canadian investigators reviewing cases over an 11-year period found that children were at neither greater nor lesser risk for TRALI. 18 Clinical presentation and morbidity were the same as for adults. Cases clustered around teenagers or those less than 1 year of age. THE SECOND ERA: RISK REDUCTION Are prevention strategies effective? Since 2004 a new TRALI era the use of low-risk plasma was entered. For most blood collectors, this approach has dictated the use of male plasma for transfusion but some have utilized HLA antibody screening of female donors. The results of these efforts are Volume 55, May 2015 TRANSFUSION 931
3 impressive. In the United Kingdom, the risk of death from TRALI nearly disappeared while the incidence decreased by almost two-thirds. 19,20 Data from the American Red Cross hemovigilance program showed that the risk of TRALI from the general inventory of distributed plasma decreased significantly from 18.6 cases per million units in 2006 to 4.2 cases per million units from 2008 to 2011 (using predominantly male plasma). 21 In a multihospital investigation, once malepredominant plasma was introduced, the incidence of TRALI decreased from % to zero over a 16-month period. 22 But the most notable of these studies was a prospective, active surveillance model at two US medical centers. These investigations showed a decrease in TRALI incidence from 2.57 per 10,000 (1:4000) in 2006, before implementation of TRALI risk reduction measures versus 0.81 per 10,000 (1:12,000) in 2009 after implementation. 15 Most importantly, TRALI deaths attributable to plasma decreased substantially over the past decade. In the United Kingdom there were seven known deaths in 2003 recorded by the Serious Hazards of Transfusion Program and in 2012 there were none. 23 FDA data are equally gratifying. There was a reduction by 63% of reported deaths after the 2007 introduction of low-risk plasma. While these data are encouraging, it is noteworthy that since 2008, the number of deaths (16-18 per year) and proportion of transfusion-related fatalities due to TRALI has leveled off at 37%, illustrating that there remains considerable room for improvement. 8 What do these data tell us? The removal of HLA, HNA, and other antibody-laden plasma from the transfusion supply chain has had a hugely beneficial effect on transfusion safety, but it has not eliminated the risk. The current status is best illustrated by American Red Cross hemovigilance data, which indicate that despite a risk reduction plasma strategy there is a 14-fold higher risk for TRALI in recipients of AB plasma than for recipients of A, B, and O plasma. 21 Additionally, RBCs now account for the largest number of TRALI cases in the United States, despite the fact that RBCs are considered a low-risk product. THE FUTURE What is (are) the mechanism(s) of TRALI? Since the 1990s the understanding of the pathogenesis of TRALI has been built on two pillars: antibodymediated and two-hit models. In both these models there is a final common pathway that entails pulmonary endothelial cell damage and capillary leakage. 24 In antibody-mediated TRALI, antibodies to HLA Class I or Class II antigens and HNA bind either neutrophils or monocytes, which leads to neutrophil activation and subsequent pulmonary edema. In the two-hit model, a patient is predisposed to TRALI by underlying factors (e.g., cardiac surgery, hematologic malignancy), which causes polymorphonuclear cell attraction, rolling, and adherence to pulmonary endothelium. 25 Transfusion of a blood component containing antibodies, cytokines, or bioactive lipids causes the release of cytokines and neutrophil activation. In the past decade elegant models have been developed, which support both models. Looney and coworkers 26 showed that TRALI is highly dependent on neutrophils. In an in vivo mouse model, depletion of neutrophils protected the animals from lung injury after MHC I monoclonal antibody challenge. In a recently developed murine antibody dependent TRALI model, lung damage was shown to require the binding of anti-mhc antibodies to their cognate antigen, stimulation of chemokines from monocytes, and a subsequent monocyte Fc-dependent injury. 27 Bux and Sachs 28 took the two-step approach further by developing a threshold model. These investigators proposed that a certain threshold must be overcome to induce a TRALI reaction. Whether TRALI occurs and whether or not it is severe depends on patient predisposition and the strength of the transfusion-related mediators. In this issue of TRANSFUSION two provocative articles challenge our current thinking on TRALI. Middelburg and van der Bom 29 argue for a new type of threshold model and a sufficient cause model. They critique the current threshold model as lumping patient and transfusion risks together and, in so doing, limit the ability to tease apart the influences of individual risk factors. They believe that TRALI is a result of multiple causal factors that together reach a pathogenic threshold for TRALI. To counteract the perceived weaknesses of the threshold model of Bux and Sachs, they propose a sufficient cause model. It is an abstract construct but it provides for representation of the interaction and effect modification of individual risk factors. It is not clear how investigators will utilize this model, but time will tell. The article by Warkentin and colleagues 30 is a bold reappraisal of the current clinically based TRALI definitions. Using heparin-induced thrombocytopenia (HIT) as the model, they propose a new classification scheme that hinges on the presence or absence of leukoreactive alloantibodies, in other words, immune versus nonimmune. The authors would designate TRALI-I in patients in which alloantibodies are identified; TRALI-II would be for antibody-negative cases. In this schema, TRALI-1a might be for HNA alloantibody positivity and TRALI-1b and TRALI-1c could implicate HLA Class I and II antibodies, respectively. They posit that this approach would reframe the thinking of what is today a clinical diagnosis and redirect the focus on developing better tests and perhaps new streams of research. This objective is worthy, 932 TRANSFUSION Volume 55, May 2015
4 given the fact there is no way to distinguish which antibodies are pathologic and there is no pathognomonic way today to make the diagnosis. One can envision how such a schema would potentially resolve those cases currently identified as possible TRALI. There is considerable merit to this proposal but one can foresee some obstacles. Will clinicians wait for test results before initiating treatment? Fulminant TRALI requires rapid intervention. What about antibodynegative cases? Will these be considered something other than TRALI? Would this approach supplant the current clinical definitions? The importance of both articles in this issue is that despite the effectiveness of risk reduction measures that have already been implemented, TRALI remains an exciting and important area of research. It is conceivable that these new approaches will lead to new ways of looking at what remains as a significant clinical problem, which could lead to creative and effective diagnostic and therapeutic solutions. What does the future hold? Assuming that the new baseline of 1 in 12,000 transfusions approximates the postplasma mitigation incidence rate and that a considerable number of cases of TRALI are not identified for reasons previously discussed, TRALI is far from eliminated. When coupled with the high mortality rate reported in elderly patients, TRALI remains an important clinical problem. The most costeffective strategy to reduce its incidence builds on the patient blood management momentum created worldwide over the past several years. The four rights of right product, right dose, right time, and right patient certainly apply in the TRALI world. Better decision making for the transfusion of all types of blood components will reduce the incidence of TRALI. The other possibilities for further risk reduction must each be weighed for their cost-benefit. These include broad screening for HNA antibodies (in addition to HLA), PLT additive solutions, and plasmareduced PLT transfusions, for whole blood and apheresis. The use of whole blood derived PLT pools is viewed as low risk for TRALI. 20 Filters have been developed that absorb antibodies and lipids, reducing TRALI-associated antibodies and neutrophil-priming activity, mitigating TRALI in an animal model. The experimental filter removes 96% of IgG as well as HLA and HNA antibodies. 31 Whether the costs of such an advance would permit widespread implementation remains to be seen. Finally, the recent approval of pathogen reduction technology of PLTs and plasma in the United States offers the potential of a new and exciting approach in the prevention of TRALI. Clearly more data and experience will be required to draw firm conclusions about its effectiveness. The work over the past 30 years has resulted in dramatic improvements in transfusion safety overall, both for infectious and for immunologic causes of transfusion sequelae. There is little doubt that much progress has been made, but there is both room for improvement as well as optimism about the tools that the transfusionist can apply to the patient who will benefit from them. In summary, we still have miles to go before we sleep. CONFLICT OF INTEREST Mark A. Popovsky, MD MPopovsky@Haemonetics.com Vice President and Chief Medical Officer Haemonetics Corporation Braintree, MA The author has disclosed no conflicts of interest. REFERENCES 1. Popovsky MA, Moore SB. Diagnostic and pathogenetic considerations in transfusion-related acute lung injury. Transfusion 1985;25: Popovsky MA, Abel MD, Moore SB. Transfusion-related acute lung injury associated with the passive transfer of antileukocyte antibodies. Am Rev Respir Dis 1983;128: Gajic O, Rana R, Winters JL, et al. Transfusion-related acute lung injury in the critically ill: prospective nested case control study. Am J Respir Crit Care Med 2007;176: Davis A, Mandal R, Johnson M, et al. A touch of TRALI. Transfusion 2008;48: Vamvakas EC, Blajchman MA. Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention. Blood 2009; 113: Kopko PM, Marshall C, Mackenzie MR, et al. Transfusionrelated acute lung injury. Report of a clinical look-back investigation. JAMA 2002;287: Rana R, Fernandez-Perez ER, Khan SA, et al. Transfusionrelated acute lung injury and pulmonary edema in critically ill patients: a retrospective study. Transfusion 2006; 46: US Food and Drug Administration (FDA). Fatalities reported to FDA following blood collection and transfusion: annual summary for fiscal year Rockville (MD): FDA; Kleinman S, Caulfield T, Chan P, et al. Toward an understanding of transfusion-related acute lung injury: statement of a consensus panel. Transfusion 2004;44: Toy P, Popovsky MA, Abraham E, et al. Transfusion-related acute lung injury: definition and review. Crit Care Med 2005;33: Volume 55, May 2015 TRANSFUSION 933
5 11. Wiersum-Osselton JC, Porcelijn L, Van Stein D, et al. [Transfusion-related acute lung injury (TRALI) in the Netherlands in ]. Ned Tijdschr Geneeskd 2008; 152: Dutch. 12. Marik PE, Corwin HL. Acute lung injury following blood transfusion: expanding the definition. Crit Care Med 2008; 36: Vlaar AP, Hofstra JJ, Determann RM, et al. The incidence, risk factors, and outcome of transfusion-related acute lung injury in a cohort of cardiac surgery patients: a prospective nested case-control study. Blood 2011;117: Gajic O, Rana R, Winters JL, et al. Transfusion-related acute lung injury in the critically ill: prospective nested case-control study. Am J Respir Crit Care Med 2007;176: Toy P, Gajic O, Bacchetti P, et al. Transfusion-related acute lung injury: incidence and risk factors. Blood 2012;119: Vlaar AP, Juffermans NP. Transfusion-related acute lung injury: a clinical review. Lancet 2013;382: Menis M, Anderson SA, Forshee RA, et al. Transfusionrelated acute lung injury and potential risk factors among the inpatient US elderly as recorded in Medicare claims data, during Transfusion 2014;54: Lieberman L, Petraszko TQ, Yi QL, et al. Transfusionrelated acute lung injury in children: a case series and review of the literature. Transfusion 2014;54: Serious Hazards of Transfusion Steering Committee. Serious Hazards of Transfusion: annual report Manchester (UK): SHOT Office; 2013 [cited 2014 June 21]. Available from: 08/SHOT-Annual Report-2012-pdf 20. Aubuchon JP. TRALI: reducing its risk while trying to understand its causes. Transfusion 2014;54: Eder AF, Dy BA, Perez JM, et al. The residual risk of transfusion-related acute lung injury at the American Red Cross ( ): limitations of a predominantly maledonor plasma mitigation strategy. Transfusion 2013;53: Arinsburg SA, Skerrett DL, Karp JK, et al. Conversion to low transfusion-related acute lung injury (TRALI)-risk plasma significantly reduces TRALI. Transfusion 2012;52: Bolton-Maggs PH, Cohen H. Serious Hazards of Transfusion (SHOT) haemovigilance and progress is improving transfusion safety. Br J Haematol 2013;163: Mair DC, Eastland T. The pathophysiology and prevention of transfusion-related acute lung injury: a review. Immunohematology 2010;26: Silliman C, Fung YL, Ball JB, et al. Transfusion-related acute lung injury (TRALI). Current concepts and misconceptions. Blood Rev 2009;23: Looney MR, Xiao S, Van Ziffle JA, et al. Neutrophils and their Fcc receptors are essential in a mouse model of transfusion-related acute lung injury. J Clin Invest 2006; 116: McKenzie CG, Kim M, Singh TK, et al. Peripheral blood monocyte-derived chemokine blockade prevents transfusion-related acute lung injury (TRALI). Blood 2014; 123: Bux J, Sachs UJ. The pathogenesis of transfusion-related acute lung injury (TRALI). Br J Haematol 2007;136: Middelburg RA, van der Bom JG. Transfusion-related acute lung injury not a two-hit, but a multicausal model. Transfusion 2015;55: Warkentin TE, Greinarcher A, Bux J. The transfusionrelated acute lung injury controversy: lessons from heparin-induced thrombocytopenia. Transfusion 2015;55: Silliman CC, Kelher MR, Khan SY, et al. Experimental prestorage filtration removes antibodies and decreases lipids in RBC supernatants mitigating TRALI in vivo. Blood 2014; 123: TRANSFUSION Volume 55, May 2015
Transfusion-related Acute Lung Injury (TRALI) University of California, San Francisco January 8, 2011
Transfusion-related Acute Lung Injury (TRALI) Mark R. Looney, M.D. Mark R. Looney, M.D. University of California, San Francisco January 8, 2011 TRALI: Case presentation 58 year-old female with degenerative
More informationCurrent Concepts Transfusion Morbidity & Mortality St. Charles Health System Grand Rounds, Bend, Oregon. Agenda. Serious Consequences of Transfusion
Current Concepts Transfusion Morbidity & Mortality St Charles Health System Grand Rounds, Bend, Oregon February 22, 2013 Mark A Popovsky, MD Associate Clinical Professor, Harvard Medical School Vice President
More informationTransfusion Reactions: What? How? What now? Part II
Transfusion Reactions: What? How? What now? Part II Margo Rollins, MD Assistant Professor of Pathology Emory University SOM Assistant Medical Director for Tissue, Transfusion & Apheresis Children s Healthcare
More informationTransfusion Associated Acute Lung Injury (TRALI)
Transfusion Associated Acute Lung Injury (TRALI) Chris Beritela, MS, MT(ASCP)SBB Area Technical Consultant Immucor, Inc. Objectives Define Transfusion-Related Acute Lung Injury (TRALI) and the role of
More informationTransfusion Associated Acute Lung Injury (TRALI) Chris Beritela, MS, MT(ASCP)SBB Area Technical Consultant Immucor, Inc.
Transfusion Associated Acute Lung Injury (TRALI) Chris Beritela, MS, MT(ASCP)SBB Area Technical Consultant Immucor, Inc. Objectives Define Transfusion-Related Acute Lung Injury (TRALI) and the role of
More informationEDUCATIONAL COMMENTARY TRANSFUSION-RELATED ACUTE LUNG INJURY
EDUCATIONAL COMMENTARY TRANSFUSION-RELATED ACUTE LUNG INJURY Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE
More informationTransfusion-related Acute Lung Injury: Report of Two Cases
294) Transfusion-related Acute Lung Injury: Report of Two Cases Čermáková Z. 1,3, Kořístka M. 2, Blahutová Š. 2, Dvořáčková J. 1, Brát R. 1, Valkovský I. 1, Hrdličková R. 2 1 Faculty of Medicine, University
More informationManagement of TRALI. Handouts. Continuing Education 5/20/2015.
Management of TRALI Christine Beritela, MS, MT(ASCP)SBB Area Technical Consultant Immucor, Inc. Massimo Mangiola, Ph.D. Director of Special Services Rhode Island Blood Center Handouts http://www.immucor.com/enus/pages/educational-program-handouts.aspx
More informationTransfusion-related acute lung injury a review
The Intensive Care Society 2009 Transfusion-related acute lung injury a review J Thachil, J Erinjeri, TD Mahambrey Transfusion-related acute lung injury (TRALI), a type of non-cardiogenic pulmonary oedema
More informationTransfusion-Related Acute Lung Injury: An Update
Transfusion-Related Acute Lung Injury: An Update Darrell J. Triulzi Transfusion-associated acute lung injury (TRALI) has emerged as a leading cause of transfusion-related morbidity and mortality. TRALI
More informationHHS Public Access Author manuscript Transfusion. Author manuscript; available in PMC 2016 May 01.
Recipient Clinical Risk Factors Predominate in Possible Transfusion-Related Acute Lung Injury Pearl Toy, MD 2, Peter Bacchetti, PhD 6, Barbara Grimes, PhD 6, Ognjen Gajic, MD 4, Edward L. Murphy, MD 2,3,
More informationTransfusion-Related Acute Lung Injury (TRALI) and Strategies for Prevention. Khalid Abdulla Sharif, MD, MRCP (UK)*
Bahrain Medical Bulletin, Vol. 29, No.4, December 2007 Transfusion-Related Acute Lung Injury (TRALI) and Strategies for Prevention Khalid Abdulla Sharif, MD, MRCP (UK)* Background: Transfusion-Related
More informationHow we View & Approach TACO
How we View & Approach TACO Annual Blood Transfusion & Hemovigilance Symposium Ede, Netherlands May 22, 3014 Mark A. Popovsky, M.D. Chief Medical Officer, Haemonetics Corporation Associate Clinical Professor,
More informationFatalities Reported to FDA Following Blood Collection and Transfusion Annual Summary for FY2015
Fatalities Reported to FDA Following Blood Collection and Transfusion Annual Summary for Fiscal Year 2015 I. Background As mentioned in the previous annual summaries of fatalities reported to the Food
More informationFatalities Reported to FDA Following Blood Collection and Transfusion
Fatalities Reported to FDA Following Blood Collection and Transfusion Annual Summary for Fiscal Year 2013 I. Background As mentioned in the previous annual summaries of fatalities reported to the FDA,
More informationRisk factors and outcome of transfusion-related acute lung injury in the critically ill: A nested case control study*
Continuing Medical Education Article Risk factors and outcome of transfusion-related acute lung injury in the critically ill: A nested case control study* Alexander P. J. Vlaar, MD; Jan M. Binnekade, PhD;
More informationTransfusion Related Respiratory Complications:
Transfusion Related Respiratory Complications: An Update on TRALI, TACO and TAD Marla C. Troughton, MD Medical Director Alabama and Central Gulf Coast Region Disclosure I have no real or apparent conflict
More informationTRALI & TACO (TNT) Triple A of Transfusion Medicine. Eric Senaldi, MD
TRALI & TACO (TNT) Triple A of Transfusion Medicine Eric Senaldi, MD 1 Statistics 1:1000 to 1:10,000 per blood product transfused 1:600 to 1:2500 per patient transfused Medicare records 2007 14.3 :100k,
More informationTransfusion Medicine Potpourri. BUMC - Phoenix Internal Medicine Residents September 29, 2015
Transfusion Medicine Potpourri BUMC - Phoenix Internal Medicine Residents September 29, 2015 Clinical case A 24 year old female with sickle cell anemia has just moved to the area and presents as a new
More informationBlood transfusions are associated with many complications,
Pulmonary Transfusion Reactions David F. Stroncek Transfusion reactions remain a common complication of transfusion therapy; reactions affecting the lungs are some of the most serious. Several different
More informationAcomplex issue commonly faced by the blood
HOW DO I...? How do we investigate and manage donors associated with a suspected case of transfusion-related acute lung injury Leon Su and Hany Kamel Acomplex issue commonly faced by the blood collection
More informationEVIDENCE BASED RED CELL TRANSFUSION. Rana Samuel, MD DIRECTOR, PATHOLOGY AND LABORATORY MEDICINE VA WNY Health Care System
EVIDENCE BASED RED CELL TRANSFUSION Rana Samuel, MD DIRECTOR, PATHOLOGY AND LABORATORY MEDICINE VA WNY Health Care System HISTORY Blood transfusion works (ie: red cell transfusion saves lives). based on
More informationNIH Public Access Author Manuscript Transfusion. Author manuscript; available in PMC 2014 September 01.
NIH Public Access Author Manuscript Published in final edited form as: Transfusion. 2013 September ; 53(9): 1940 1947. doi:10.1111/trf.12064. Lot-to-Lot Variability in HLA Antibody Screening Using a Multiplexed
More informationTACO: a call to action
TACO: a call to action Johanna (Jo) Wiersum-Osselton TRIP (Transfusion and Transplantation Reactions in Patients) Also: Sanquin donor physician No financial conflicts Photo: University of Virginia website
More informationConcentrated Wash (10X)
INSTRUCTIONS FOR USE DonorScreen-HLA Class I and Class II Additional Reagents Concentrated Wash (10X) 303456 (DonorScreen-HLA Class I and Class II Additional Reagents) 404563 (Concentrated Wash (10X))
More informationREVIEW. Toward an understanding of transfusion-related acute lung injury: statement of a consensus panel
Blackwell Science, LtdOxford, UKTRFTransfusion0041-11322004 American Association of Blood BanksDecember 2004441217741789Review ArticleTRALI CONSENSUS PANEL STATEMENTKLEINMAN ET AL. REVIEW Toward an understanding
More informationBlood Management: Improve Transfusion, Decrease Costs!
Management: Improve Transfusion, Decrease Costs! Risks of Transfusion Management Issues Strategies to Implement Example of UAB Hospital Margaret Fritsma, MA, MT(ASCP)SBB mgfritsma@charter.net What is Management?
More informationNIH Public Access Author Manuscript Best Pract Res Clin Anaesthesiol. Author manuscript; available in PMC 2009 October 26.
NIH Public Access Author Manuscript Published in final edited form as: Best Pract Res Clin Anaesthesiol. 2007 January 6; 21(2): 183 193. doi:10.1016/j.bpa.2007.01.003. TRALI - Definition, mechanisms, incidence
More informationTransfusion Pitfalls. Objectives. Packed Red Blood Cells. TRICC trial (subgroups): Is transfusion always good? Components
Objectives Transfusion Pitfalls Gregory W. Hendey, MD, FACEP Professor and Chief UCSF Fresno, Emergency Medicine To list risks and benefits of various blood products To discuss controversy over liberal
More informationTransfusion reactions illustrated
Transfusion reactions illustrated Chapter 1 Transfusion practice 1 Procedure of transfusion practice In general, transfusion-associated incidents occur due to multiple errors, most of which occur in the
More informationREPORT OF TRANSFUSION ADVERSE REACTION TO BLOOD CENTERS
REPORT OF TRANSFUSION ADVERSE REACTION TO BLOOD CENTERS INSTRUCTIONS: Send the form to ALL blood centers that provided blood components to this patient. Timely reporting is important, so that, if appropriate,
More informationTRIP Annual Report 2009 Trends in 7 years of hemovigilance reporting. Martin Schipperus. Director Dutch National Hemovigilance Office TRIP
TRIP Annual Report 2009 Trends in 7 years of hemovigilance reporting Martin Schipperus Director Dutch National Hemovigilance Office TRIP TRIP annual report 2009 Participation Overview reports 2003 2009
More informationApproach to a patient with suspected blood transfusion reaction. Raju Vaddepally, MD
Approach to a patient with suspected blood transfusion reaction Raju Vaddepally, MD Goals Detection of Acute Transfusion Reactions (ATR) Clinical and Laboratory Evaluation of ATR Management of individual
More informationIMPLICATION OF HLA ANTIBODIES & TRALI MITIGATION PROGRAM
IMPLICATION OF HLA ANTIBODIES & TRALI MITIGATION PROGRAM LEARN Webinars: Management of TRALI June 23, 2015 2:00 3:30 pm (EDT) Massimo Mangiola, Ph.D. Director, Special Services Rhode Island Blood Center
More information25/10/2017. Clinical Relevance of the HLA System in Blood Transfusion. Outline of talk. Major Histocompatibility Complex
Clinical Relevance of the HLA System in Blood Transfusion Dr Colin J Brown PhD FRCPath. October 2017 Outline of talk HLA genes, structure and function HLA and immune complications of transfusion TA-GVHD
More informationTRANSFUSION REACTIONS
14 TRANSFUSION REACTIONS 14.1 INTRODUCTION Transfusion of blood and blood products are reported to cause reactions during or after procedure specially in patients who receive multiple transfusions. These
More informationTransfusion Reactions. Directed by M-azad March 2012
Transfusion Reactions Directed by M-azad March 2012 Transfusion Reactions are Adverse reactions associated with the transfusion of blood and its components Transfusion reactions Non-threatening to fatal
More information2/2/2011. Blood Components and Transfusions. Why Blood Transfusion?
Blood Components and Transfusions Describe blood components Identify nursing responsibilities r/t blood transfusion Discuss factors r/t blood transfusion including blood typing, Rh factor, and cross matching
More informationTransfusion-Related Acute Lung Injury* Mark R. Looney, MD; Michael A. Gropper, MD, PhD, FCCP; and Michael A. Matthay, MD, FCCP
critical care review Transfusion-Related Acute Lung Injury* A Review Mark R. Looney, MD; Michael A. Gropper, MD, PhD, FCCP; and Michael A. Matthay, MD, FCCP Transfusion-related acute lung injury (TRALI)
More informationPrevention of TACO what Haemovigilance data tell us
Prevention of TACO what Haemovigilance data tell us Swisstransfusion, Genève 6. Septembre 03 Markus Jutzi, Morven Rüesch Clinical Reviewer Haemovigilance, Swissmedic Swissmedic Schweizerisches Heilmittelinstitut
More informationThree decades of transfusion Toronto, Critical Care Canada Forum, October 30, 2014.
Three decades of transfusion Toronto, Critical Care Canada Forum, October 30, 2014. Jacques Lacroix For the Canadian Critical Care Trials Group and the PALISI Network Pediatric Intensive Care Unit Sainte-Justine
More informationTransfusion-related acute lung injury Kathryn E. Webert a,c and Morris A. Blajchman a,b,c
Transfusion-related acute lung injury Kathryn E. Webert a,c and Morris A. Blajchman a,b,c Purpose of review Transfusion-related acute lung injury is an uncommon complication of blood transfusion typically
More informationGUIDANCE DOCUMENT FOR MASSIVE HEMORRHAGE MANAGEMENT IN ADULTS
GUIDANCE DOCUMENT FOR MASSIVE HEMORRHAGE MANAGEMENT IN ADULTS 1.0 Definitions & Acronyms 1.1 Massive Hemorrhage Event (MHE): Transfusion of a volume of blood components equivalent to a patient s estimated
More informationFigure 1: ATEs related to transfused products per year (N=1,040). 8
Table of Contents Table of Contents Acknowledgement 4 Executive Summary 5 Methodology 7 Blood Products and ATEs 8 Table 1A: Adverse Transfusion Events (ATEs),N (%) by type of product and year. 8 Figure
More informationEUROPEAN COMMISSION DIRECTORATE GENERAL FOR HEALTH AND FOOD SAFETY
Ref. Ares(2016)5909621-13/10/2016 EUROPEAN COMMISSION DIRECTORATE GENERAL FOR HEALTH AND FOOD SAFETY Directorate B - Health systems, medical products and innovation B4 Medical products: quality, safety
More informationTRANSFUSION REACTION AMONG THE BLOOD RECIPIENT - A STUDY OF 120 CASES
TRANSFUSION REACTION AMONG THE BLOOD RECIPIENT - A STUDY OF 120 CASES Chowdhury FS 1, Biswas J 2, Siddiqui MAE 3, Hoque MM 4, Adnan SK 5 Abstract: Context: Blood transfusion is a life saving procedure.
More informationAcute Transfusion Reactions (Allergic, Hypotensive and Severe Febrile) (ATR) n=296 11
REACTIONS IN PATIENTS: Serious adverse reactions including EU definition ANNUAL SHOT REPORT 2015 Acute Transfusion Reactions (Allergic, Hypotensive and Severe Febrile) (ATR) n=296 11 Authors: Janet Birchall,
More informationFrequency and Pattern of Noninfectious Adverse Transfusion Reactions at a Tertiary Care Hospital in Korea
Original Article Transfusion Medicine Ann Lab Med 2016;36:36-41 http://dx.doi.org/10.3343/alm.2016.36.1.36 ISSN 2234-3806 eissn 2234-3814 Frequency and Pattern of Noninfectious Adverse Transfusion Reactions
More informationTransfusion Medicine. Joint ASH and AABB Educational Session
Transfusion Medicine Joint ASH and AABB Educational Session Lawrence T. Goodnough, Patricia E. Hewitt, and Christopher C. Silliman In the vein-to-vein flow of blood from donor to patient, the role of the
More informationClinical Relevance of the HLA System in Blood Transfusion. Dr Colin J Brown PhD FRCPath. October 2017
Clinical Relevance of the HLA System in Blood Transfusion Dr Colin J Brown PhD FRCPath. October 2017 Outline of talk HLA genes, structure and function HLA and immune complications of transfusion TA-GVHD
More informationBlood is serious business
Transfusion at RCH BLOOD TRANSFUSION Anthea Greenway Dept of Clinical Haematology >10000 fresh blood products per year Supports craniofacial and cardiac surgery Support bone marrow, liver transplant and
More informationBlood Reviews 23 (2009) Contents lists available at ScienceDirect. Blood Reviews. journal homepage:
Blood Reviews 23 (2009) 245 255 Contents lists available at ScienceDirect Blood Reviews journal homepage: www.elsevier.com/locate/blre REVIEW Transfusion-related acute lung injury (TRALI): Current concepts
More informationSuccessful use of extracorporeal membrane oxygenation in a patient with transfusion-related acute lung injury
Case Report Crit Care & Shock (2011) 14:40-45 Successful use of extracorporeal membrane oxygenation in a patient with transfusion-related acute lung injury Jarrod Mosier, Terence O Keeffe, Holly Graham,
More informationPatient Blood Management. Marisa B. Marques, MD UAB Department of Pathology November 17, 2016
Patient Blood Management Marisa B. Marques, MD UAB Department of Pathology November 17, 2016 Learning Objectives Upon completion of the session, the participant will: 1) Differentiate between the various
More informationTRANSFUSION TRANSMITTED INJURIES SURVEILLANCE SYSTEM (TTISS): SUMMARY RESULTS. 1 P age
TRANSFUSION TRANSMITTED INJURIES SURVEILLANCE SYSTEM (TTISS): 2009-2013 SUMMARY RESULTS 1 P age Acknowledgments: The development of the Transfusion Transmitted Surveillance System (TTISS) would not have
More informationPatient Blood Management: Enough is Enough
Patient Blood Management: Enough is Enough Richard Benjamin, MBChB, PhD, FRCPath Professor of Pathology Georgetown University Medical Center Washington, D.C. Chief Medical Officer Cerus Corporation Concord,
More informationINVESTIGATION OF ADVERSE TRANSFUSION REACTIONS TABLE OF RECOMMENDED TESTS. Type of Reaction Presentation Recommended Tests Follow-up Tests
Minor Allergic (Urticarial) Urticaria, pruritis, flushing, rash If skin reaction only and mild hives/ rash
More informationBoot Camp Transfusion Reactions
Boot Camp Transfusion Reactions Dr. Kristine Roland Regional Medical Lead for Transfusion Medicine, VCH Objectives By the end of this session, you should be able to: Describe in common language the potential
More informationTRANSFUSION PRACTICE
Blackwell Science, LtdOxford, UKTRFTransfusion0041-11322004 American Association of Blood BanksJanuary 2004441Original ArticleLEUKOREDUCTION DECREASES FEBRILE TRANSFUSION REACTIONSKING ET AL. TRANSFUSION
More informationImplementation and outcomes of a transfusion-related acute lung injury surveillance programme and study of HLA/HNA alloimmunisation in blood donors
ORIGINAL ARTICLE Implementation and outcomes of a transfusion-related acute lung injury surveillance programme and study of HLA/HNA alloimmunisation in blood donors Laura Porretti 1, Alessandra Cattaneo
More informationSepsis 3.0: The Impact on Quality Improvement Programs
Sepsis 3.0: The Impact on Quality Improvement Programs Mitchell M. Levy MD, MCCM Professor of Medicine Chief, Division of Pulmonary, Sleep, and Critical Care Warren Alpert Medical School of Brown University
More informationAssessing thrombocytopenia in the intensive care unit: The past, present, and future
Assessing thrombocytopenia in the intensive care unit: The past, present, and future Ryan Zarychanski MD MSc FRCPC Sections of Critical Care and of Hematology, University of Manitoba Disclosures FINANCIAL
More informationTACO Est ce que cette complication transfusionnelle peut être prédite et prévenue?
TACO Est ce que cette complication transfusionnelle peut être prédite et prévenue? Jeannie Callum, BA, MD, FRCPC, CTBS En vertu des règles de divulgation, je suis tenu de vous Nothing dire que je suis
More informationCitation for published version (APA): Müller, M. C. A. (2014). Coagulopathy and plasma transfusion in critically ill patients.
UvA-DARE (Digital Academic Repository) Coagulopathy and plasma transfusion in critically ill patients Müller, Marcella Link to publication Citation for published version (APA): Müller, M. C. A. (2014).
More informationREASONS FOR MOVING TOWARD A PATIENT-CENTRIC PARADIGM OF CLINICAL TRANSFUSION MEDICINE PRACTICE
REASONS FOR MOVING TOWARD A PATIENT-CENTRIC PARADIGM OF CLINICAL TRANSFUSION MEDICINE PRACTICE Eleftherios C. Vamvakas Swisstransfusion 2012 Congress of the Swiss Association for Transfusion Medicine Basel,
More informationPEDIATRIC TRANSFUSION MEDICINE AS A SUB-SPECIALITY TO TRANSFUSION MEDICINE
PEDIATRIC TRANSFUSION MEDICINE AS A SUB-SPECIALITY TO TRANSFUSION MEDICINE Prof. Neelam Marwaha MD; FAMS; FISHTM. Head, Dept. of Transfusion Medicine PGIMER Chandigarh Dr. Hari Krishan Dhawan MD. Assistant
More informationAn Approach to the Patient Refractory to Platelets Transfusion. Harold Alvarez, MD
Harold Alvarez, MD Objectives Explain the etiology of platelet refractoriness Discuss the different types of platelet refractoriness Describe how platelet refractoriness is diagnosed Discuss different
More informationStorage medium and transfusion transmitted bacterial infections
Storage medium and transfusion transmitted bacterial infections Aukje Kreuger Phd Student Center for Clinical Transfusion Research, Sanquin, Leiden Department of Epidemiology, LUMC, Leiden TTIP meeting,
More informationTransfusion Reactions:
Transfusion Reactions: Melissa R. George, D.O., F.C.A.P. Medical Director, Transfusion Medicine & Apheresis Penn State Milton S. Hershey Medical Center Office: HG069, Phone: 717-531-4627 E-mail: mgeorge5@hmc.psu.edu
More informationTransfusion & Mortality. Philippe Van der Linden MD, PhD
Transfusion & Mortality Philippe Van der Linden MD, PhD Conflict of Interest Disclosure In the past 5 years, I have received honoraria or travel support for consulting or lecturing from the following companies:
More informationCOMPLICATIONS OF BLOOD TRANSFUSIONS. :Prepared by Dr. Nawal Mogales & Dr. Mohammed Aqlan
COMPLICATIONS OF BLOOD TRANSFUSIONS :Prepared by Dr. Nawal Mogales & Dr. Mohammed Aqlan COMPLICATIONS OF TRANSFUSIONS Transfusion reaction may result from either : A. Immune transfusion reaction. B. Non
More informationBlood Product Utilization A Mythbusters! Style Review. Amanda Haynes, DO 4/28/18
Blood Product Utilization A Mythbusters! Style Review Amanda Haynes, DO 4/28/18 Objectives Describe concepts in Patient Blood Management Review common misconceptions surrounding blood transfusion Summarize
More informationMary Berg, M.D. Medical Director, Transfusion Services Associate Professor of Pathology University of Colorado Hospital
Transfusion Reactions/Complications Mary Berg, M.D. Medical Director, Transfusion Services Associate Professor of Pathology University of Colorado Hospital Acute Transfusion Reactions Can be seen with
More informationHave you ever managed patients who have experienced an adverse reaction to transfusion?
Have you ever managed patients who have experienced an adverse reaction to transfusion? A. Yes, often B. Yes, occasionally C. No A. 1 in 30 units? B. 1 in 100? C. 1 in 1000? D. 1 in 10,000? SHOT collects
More informationThe pathogenesis of transfusion-related acute lung injury (TRALI)
review The pathogenesis of transfusion-related acute lung injury (TRALI) Jürgen Bux 1 and Ulrich J. H. Sachs 2 1 DRK-Blood Service West of the German Red Cross, Hagen, and 2 Institute for Clinical Immunology
More informationTransfusions occur commonly in pediatrics, particularly
TRANSFUSION ORIGINALCOMPLICATIONS ARTICLE Transfusion reactions in pediatric compared with adult patients: a look at rate, reaction type, and associated products Fredrick D. Oakley, 1 Marcella Woods, Shanna
More informationChest diseases Hospital Laboratory Hematology Practice guidelines
Chest diseases Hospital Laboratory Hematology Practice guidelines Title RBCs transfusion in Adults SOP Code Policy Owner Hematology Unit Section Hematology Prepared By Dr. Taher Ahmed Abdelhameed Issuing
More informationLeukocyte Depletion in Cardiac Surgery and Cardiology
Leukocyte Depletion in Cardiac Surgery and Cardiology Leukocyte Depletion in Cardiac Surgery and Cardiology Editors Georg Matheis Frankfurt Anton Moritz Frankfurt Martin Scholz Frankfurt 32 figures and
More informationPulmonary complications in the Elderly. Paula Bolton-Maggs Medical Director
Pulmonary complications in the Elderly Paula Bolton-Maggs Medical Director What does SHOT do? Serious Hazards of Transfusion Collect data on serious adverse reactions and events related to transfusion
More informationJovona Powelson, B.S. MLT (ASCP) Director of Laboratories
Jovona Powelson, B.S. MLT (ASCP) Director of Laboratories Blood Products From the Donor to You Objectives Deliver a brief virtual tour of a blood center. Describe the number of donors needed to meet the
More informationRisk factors for fatal outcome in surgical patients with postoperative. aspiration pneumonia
Original article Risk factors for fatal outcome in surgical patients with postoperative aspiration pneumonia Peter Studer 1, Genevieve Räber 1, Daniel Ott 2, Daniel Candinas 1, Beat Schnüriger 1 1 Department
More informationSteroids for ARDS. Clinical Problem. Management
Steroids for ARDS James Beck Clinical Problem A 60 year old lady re-presented to ICU with respiratory failure. She had previously been admitted for fluid management and electrolyte correction having presented
More informationTransfusion Reactions
Transfusion Reactions From A to T Provincial Blood Coordinating Program Daphne Osborne MN PANC (C) RN We want you to know Definition Appropriate actions Classification Complete case studies Transfusion
More informationYOUR PARTNER IN PATIENT CARE AN EDUCATIONAL RESOURCE PUBLISHED BY AMERICAN RED CROSS BLOOD SERVICES SPRING 2009
PLUS YOUR PARTNER IN PATIENT CARE AN EDUCATIONAL RESOURCE PUBLISHED BY AMERICAN RED CROSS BLOOD SERVICES SPRING 2009 TRANSFUSION-TRANSMITTED BABESIOSIS INFECTION UP IN U.S. During January 2009, the US
More informationAcrodose Systems A total solution for pre-storage pooling and bacteria detection of whole blood-derived platelets
Acrodose Systems A total solution for pre-storage pooling and bacteria detection of whole blood-derived platelets Acrodose Systems A new approach to platelet transfusion therapy Improves Safety Increases
More informationBlood Safety and Surveillance
Blood Safety and Surveillance Alfred DeMaria, Jr. MD Medical Director, State Epidemiologist Anthony Osinski, MPH Epidemiologist, Hemovigilance Coordinator Melissa Cumming, MS Antibiotic Resistance and
More informationTRANSFUSION ASSOCIATED DISEASE, RECALL, OR COMPLICATION INVESTIGATION POLICY I. FATALITIES AND COMPLICATIONS ASSOCIATED WITH TRANSFUSION:
I. FATALITIES AND COMPLICATIONS ASSOCIATED WITH TRANSFUSION: A. TRANSFUSION RELATED FATALITY: FDA and MEDIC must be notified immediately, and subsequently in writing, when a possible transfusion related
More information7/4/2015. diffuse lung injury resulting in noncardiogenic pulmonary edema due to increase in capillary permeability
Leanna R. Miller, RN, MN, CCRN-CMC, PCCN-CSC, CEN, CNRN, CMSRN, NP Education Specialist LRM Consulting Nashville, TN Objectives Identify the 5 criteria for the diagnosis of ARDS. Discuss the common etiologies
More informationCURRENT COURSE OFFERINGS
The American Red Cross offers regular educational opportunities as a convenient way for healthcare providers to receive relevant blood banking and transfusion medicine information. The bi-monthly sessions,
More informationTransfusion-related acute lung injury
Transfusion-related acute lung injury Etiological research and its methodological challenges Rutger A. Middelburg The work described in this thesis was performed at the department of Clinical Epidemiology
More informationDefinitions of Current SHOT Categories & What to Report
Definitions of Current SHOT Categories & What to Report Revised March 2011 1 ADVERSE EVENTS TERM DEFINITION WHAT TO REPORT IBCT - Wrong Blood Transfused (Incorrect Blood Component Transfused) Where a patient
More informationIt s not just allo-antibodies that a red cell transfusion can stimulate
It s not just allo-antibodies that a red cell transfusion can stimulate Associate Professor Ralph Green Laboratory Medicine RMIT University Melbourne, Australia Transfusion practice Minimise risk of transmitting
More informationImmunological transfusion reactions
Immunological transfusion reactions Immunological transfusion reactions can be hemolytic or non-hemolytic in nature. Both types can be separated into acute (those occurring immediately after transfusion)
More informationTransfusion 2004: Current Practice Standards. Kay Elliott, MT (ASCP) SBB SWMC Transfusion Service
Transfusion 2004: Current Practice Standards Kay Elliott, MT (ASCP) SBB SWMC Transfusion Service Massive Transfusion Protocol (MTP) When should it be activated? Massive bleeding i.e. loss of one blood
More informationDesigning and Testing a Computer-Based Screening System for Transfusion-Related Acute Lung Injury
Coagulation and Transfusion Medicine / AUTOMATIC COMPUTER SCREENING FOR TRANSFUSION REACTIONS Designing and Testing a Computer-Based Screening System for Transfusion-Related Acute Lung Injury Heather E.
More informationBack to the Future: Updated Guidelines for Evaluation and Management of Adrenal Insufficiency in the Critically Ill
Back to the Future: Updated Guidelines for Evaluation and Management of Adrenal Insufficiency in the Critically Ill Joe Palumbo PGY-2 Critical Care Pharmacy Resident Buffalo General Medical Center Disclosures
More informationAs the risks of infectious disease transmission by transfusion
Noninfectious Complications of Blood Transfusion Anne F. Eder, MD, PhD; Linda A. Chambers, MD Context. Serious noninfectious complications are far more likely to occur than viral disease transmission from
More informationBlood product transfusion in emergency department patients: a case-control study of practice patterns and impact on outcome
Beyer et al. International Journal of Emergency Medicine (2017) 10:5 DOI 10.1186/s12245-017-0133-z International Journal of Emergency Medicine ORIGINAL RESEARCH Open Access Blood product transfusion in
More information